conmed corp. - CNMD

CNMD

Close Chg Chg %
32.12 0.49 1.53%

Closed Market

32.61

+0.49 (1.53%)

Volume: 1.23M

Last Updated:

Jun 18, 2026, 3:59 PM EDT

Company Overview: conmed corp. - CNMD

CNMD Key Data

Open

$32.10

Day Range

32.10 - 32.92

52 Week Range

31.84 - 56.64

Market Cap

$980.96M

Shares Outstanding

30.11M

Public Float

29.98M

Beta

0.92

Rev. Per Employee

N/A

P/E Ratio

18.38

EPS

$1.78

Yield

245.55%

Dividend

$0.20

EX-DIVIDEND DATE

Sep 15, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

554.24K

 

CNMD Performance

1 Week
 
-6.30%
 
1 Month
 
-12.49%
 
3 Months
 
-9.35%
 
1 Year
 
-37.57%
 
5 Years
 
-75.94%
 

CNMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About conmed corp. - CNMD

CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

CNMD At a Glance

CONMED Corp.
11311 Concept Boulevard
Largo, Florida 33773
Phone 1-727-392-6464 Revenue 1.37B
Industry Medical Specialties Net Income 47.06M
Sector Health Technology 2025 Sales Growth 5.509%
Fiscal Year-end 12 / 2026 Employees 3,900
View SEC Filings

CNMD Valuation

P/E Current 18.112
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 26.877
Price to Sales Ratio 0.92
Price to Book Ratio 1.217
Price to Cash Flow Ratio 7.41
Enterprise Value to EBITDA 10.913
Enterprise Value to Sales 1.536
Total Debt to Enterprise Value 0.42

CNMD Efficiency

Revenue/Employee 352,434.615
Income Per Employee 12,065.385
Receivables Turnover 5.546
Total Asset Turnover 0.593

CNMD Liquidity

Current Ratio 2.136
Quick Ratio 1.007
Cash Ratio 0.13

CNMD Profitability

Gross Margin 52.774
Operating Margin 10.268
Pretax Margin 5.174
Net Margin 3.423
Return on Assets 2.032
Return on Equity 4.715
Return on Total Capital 2.45
Return on Invested Capital 2.469

CNMD Capital Structure

Total Debt to Total Equity 85.905
Total Debt to Total Capital 46.209
Total Debt to Total Assets 38.159
Long-Term Debt to Equity 85.003
Long-Term Debt to Total Capital 45.724
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Conmed Corp. - CNMD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.03B 1.24B 1.30B 1.37B
Sales Growth
+1.41% +20.44% +4.98% +5.51%
Cost of Goods Sold (COGS) incl D&A
502.37M 597.89M 608.16M 649.12M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
49.76M 51.40M 51.30M 52.34M
Depreciation
16.05M 16.20M 16.61M 17.14M
Amortization of Intangibles
33.70M 35.20M 34.70M 35.20M
COGS Growth
+5.25% +19.01% +1.72% +6.74%
Gross Income
528.02M 643.07M 694.57M 725.38M
Gross Income Growth
-1.99% +21.79% +8.01% +4.43%
Gross Profit Margin
+51.24% +51.82% +53.32% +52.77%
2022 2023 2024 2025 5-year trend
SG&A Expense
444.39M 512.28M 530.35M 584.24M
Research & Development
47.15M 52.60M 54.43M 55.88M
Other SG&A
397.24M 459.68M 475.92M 528.36M
SGA Growth
+5.23% +15.28% +3.53% +10.16%
Other Operating Expense
- - - -
-
Unusual Expense
141.61M 18.81M (30.69M) 38.34M
EBIT after Unusual Expense
(57.98M) 111.97M 194.92M 102.79M
Non Operating Income/Expense
16.02M 8.63M 5.41M (588.00K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
28.91M 39.77M 37.30M 31.09M
Interest Expense Growth
-18.54% +37.61% -6.23% -16.65%
Gross Interest Expense
28.91M 39.77M 37.30M 31.09M
Interest Capitalized
- - - -
-
Pretax Income
(70.86M) 80.83M 163.03M 71.12M
Pretax Income Growth
-196.93% +214.06% +101.70% -56.38%
Pretax Margin
-6.88% +6.51% +12.51% +5.17%
Income Tax
9.72M 16.37M 30.61M 24.06M
Income Tax - Current - Domestic
1.68M 5.89M 6.96M 7.79M
Income Tax - Current - Foreign
14.08M 9.78M 11.45M 12.75M
Income Tax - Deferred - Domestic
(5.73M) 1.93M 11.03M 4.92M
Income Tax - Deferred - Foreign
(310.00K) (1.23M) 1.17M (1.40M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(80.58M) 64.46M 132.42M 47.05M
Minority Interest Expense
- - - -
-
Net Income
(80.58M) 64.46M 132.42M 47.05M
Net Income Growth
-228.84% +179.99% +105.44% -64.47%
Net Margin Growth
-7.82% +5.19% +10.17% +3.42%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(80.58M) 64.46M 132.42M 47.05M
Preferred Dividends
- - - -
-
Net Income Available to Common
(80.58M) 64.46M 132.42M 47.05M
EPS (Basic)
-2.6825 2.1018 4.293 1.5161
EPS (Basic) Growth
-225.08% +178.35% +104.25% -64.68%
Basic Shares Outstanding
30.04M 30.67M 30.85M 31.04M
EPS (Diluted)
-2.6825 2.0432 4.2511 1.5106
EPS (Diluted) Growth
-238.18% +176.17% +108.06% -64.47%
Diluted Shares Outstanding
30.04M 31.55M 31.15M 31.15M
EBITDA
133.38M 182.19M 215.53M 193.47M
EBITDA Growth
-19.76% +36.59% +18.30% -10.23%
EBITDA Margin
+12.94% +14.68% +16.54% +14.08%

Snapshot

Average Recommendation HOLD Average Target Price 39.60
Number of Ratings 6 Current Quarters Estimate 1.108
FY Report Date 06 / 2026 Current Year's Estimate 4.365
Last Quarter’s Earnings 0.89 Median PE on CY Estimate N/A
Year Ago Earnings 4.59 Next Fiscal Year Estimate 4.788
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 6 6 6
Mean Estimate 1.11 1.04 4.37 4.79
High Estimates 1.12 1.07 4.40 4.98
Low Estimate 1.07 1.02 4.30 4.67
Coefficient of Variance 1.75 2.28 0.82 2.34

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 6 6 6
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Conmed Corp. - CNMD

Date Name Shares Transaction Value
Mar 11, 2026 Brent Lalomia Executive VP RA, QA 941 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Brent Lalomia Executive VP RA, QA 915 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $39.9 per share 36,508.50
Mar 11, 2026 Brent Lalomia Executive VP RA, QA N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 25, 2025 Richard Glaze Chief Information Officer N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.21 per share 0.00
Sep 10, 2025 Kim Kelderman Director 500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 10, 2025 Kim Kelderman Director 6,227 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Conmed Corp. in the News